The General Motors Duramax turbodiesel engine family has evolved a lot since these heavy-duty pickup truck engines first came onto the scene in the early 2000s. Among the iterations of the Duramax ...

Eli Lilly (LLY) faces a downgrade to Reduce from HSBC analyst Rajesh Kumar, who cut his price target from $1,070 to $850, citing overestimated obesity drug market size ($80B-$120B by 2032 versus ...

Eli Lilly (LLY) shares slipped in the premarket on Tuesday after HSBC downgraded the weight loss drugmaker to Reduce from Hold, issuing the pharma giant’s only sell-equivalent rating on Wall Street, ...

Stock futures ticked higher on Tuesday as investors remained cautious amid escalating tensions involving Iran, which have pushed oil prices higher and added to inflation concerns, while attention also ...

The analyst cut its rating on LLY to "reduce" from "hold" Eli Lilly And Co (NYSE:LLY) stock is down 2.2% to trade at $967.06 at last glance, after a downgrade at HSBC "reduce" from "hold." The analyst ...

Eli Lilly (LLY) is down to the $937 area as investors await an April FDA decision on its oral obesity pill, orforglipron. Moreover, shares of Eli Lilly rival Novo Nordisk (NVO) are down 25% year to ...

Eli Lilly (NYSE:LLY) stock is down 5% in Tuesday afternoon trading, with shares falling to $937 from a prior close of $989.12. The move adds to a rough stretch for the stock, which is now down 13% ...

HSBC analysts just slashed their recommendation on the world's most valuable pharmaceutical company, Eli Lilly, signaling a potential cooling period for the red-hot obesity drug trade that has come to ...

The healthcare sector is selling off in lockstep with the broader market. Eli Lilly’s growth is heavily dependent on weight loss drugs. The healthcare sector is reasonably valued. Eli Lilly makes many ...